Prospective Analysis of Discordant Results between Biochemical Markers and Biopsy in Patients with Chronic Hepatitis C
Top Cited Papers
- 1 August 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 50 (8) , 1344-1355
- https://doi.org/10.1373/clinchem.2004.032227
Abstract
Background: The FibroTest and ActiTest are noninvasive biochemical markers of liver injury that are intended for use as alternatives to liver biopsy in patients with chronic hepatitis C. The aims of this study were to assess the quality of biopsy and the prevalence of discordances between biopsy and markers, to identify factors associated with discordances, and to attribute these discordances to either markers or biopsy failure.Keywords
This publication has 26 references indexed in Scilit:
- The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis CHepatology, 2004
- Sampling variability of liver fibrosis in chronic hepatitis CHepatology, 2003
- Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the diseaseJournal of Hepatology, 2003
- Noninvasive Prediction of Fibrosis in Patients With Chronic Hepatitis CHepatology, 2003
- Biochemical Markers of Fibrosis in Patients with Chronic Hepatitis C: A Comparison with Prothrombin Time, Platelet Count, and Age–Platelet IndexDigestive Diseases and Sciences, 2003
- Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infectionAmerican Journal of Gastroenterology, 2002
- Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis CAmerican Journal of Gastroenterology, 2002
- Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective studyThe Lancet, 2001
- Liver BiopsyNew England Journal of Medicine, 2001
- Appropriateness of Liver BiopsyCanadian Journal of Gastroenterology and Hepatology, 2000